Evaluating the Efficacy and Safety of a Unani formulation in Melasma.

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to Evaluate the Efficacy and Safety of a Unani Pharmacopoeial Formulation Ghaza Husn-e-Afza in the treatment of Kalaf (Melasma) - NA

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059114

Enrollment

Registered

2023-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Ghaza Husn-e-Afza (With Water): Dosage Form: Tila Dose: As per required at bedtime Mode of Administration: Local Composition: 1.Post Narangi (Citrus sinensis) 2.Tukhm-e-Baqla Muqasshar

Eligibility

Inclusion criteria

Inclusion criteria: Participants of any gender in the age group of 18-60 years. Participants having bilateral symmetrical or asymmetrical brown macules on face (nose, forehead, upper lip and cheeks & chin ). Participants who are willing to participate and comply with the protocol and to sign IEC approved ICF.

Exclusion criteria

Exclusion criteria: Participants aged 60 years of age Pregnant or Lactating Women Mentally retarded person Known allergy, sensitivity or intolerance to the study drug or any of its ingredients Known case of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS etc

Design outcomes

Primary

Measure	Time frame
25 % reduction in MASI Score from baselineTimepoint: 8 Weeks	—

Secondary

Measure	Time frame
Melasma Quality of LifeTimepoint: 8 Weeks	—

Countries

India

Contacts

Public ContactDr Altamash Kaleem

National Research Institiute of Unani Medicine for Skin Disorders

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026